Latest Breaking News On - Co national principal investigator - Page 1 : comparemela.com

Contego Medical Announces One-Year Outcomes From the Performance II Carotid Stent Trial

Contego Medical Announces One-Year Outcomes From the Performance II Carotid Stent Trial
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

William grayStacy enxing sengDivision of cardiovascular diseasesProduct serviceCenters for medicare medicaid servicesNational principal investigatorContego medical incMain line healthMedical announces one year outcomes fromMedical incVascular interventional advancesSystem chiefCardiovascular diseasesCo national principal investigatorContego medicalMedicaid services

PERFORMANCE II Carotid Stent Trial One-Year Outcomes Released at VIVA23

Contego Medical Inc. announced the presentation of late-breaking clinical results from the PERFORMANCE II carotid stent trial at the annual VIVA (Vascular InterVentional Advances), VIVA 23, being held Oct. 30-Nov. 2 in Las Vegas, NV. The PERFORMANCE II is a prospective, multicenter study evaluating the safety and effectiveness of the Neuroguard IEP System in 305 patients at 40 clinical sites.

Stacy enxing sengWilliam grayLas vegasContego medical incCenters for medicare medicaid servicesViva foundation octDivision of cardiovascular diseasesMain line healthNational principal investigatorContego medicalVascular interventional advancesAviva foundationSystem chiefCardiovascular diseasesCo national principal investigatorMedicaid services

CONTEGO MEDICAL ANNOUNCES START OF ENROLLMENT IN PERFORMANCE III DIRECT TRANSCAROTID ACCESS STENTING TRIAL

RALEIGH, N.C., Oct. 6, 2023 /PRNewswire/ Contego Medical Inc., a company dedicated to improving patient outcomes and procedural efficiency in t.

Robert mendesStacy enxing sengSean lydenDepartment of vascular surgery at cleveland clinicContego medical incNational principal investigatorPrnewswire contego medical incDrug administrationContego medicalUniversity of north carolina rex hospitalMedical incDirect systemInvestigational device exemptionRavish sacharOperating partnerLightstone ventures

BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy results for the ongoing Phase III pivotal trial of CardiAMP® Cell Therapy for Heart Failure (CardiAMP HF, clinicaltrials.gov Identifier: NCT02438306), for which the FDA granted Breakthrough Designation fo

United statesUniversity of wisconsinPeter altmanCarl pepineMiranda petoDavid mcclungStatistical data analysis centerExchange commission onUniversity of florida at gainesvilleNational principal investigatorBiocardia incNational principal investigatorsMaryland stem cell research fundCardiamp cell therapy programCell therapyHeart failure

BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial - BioCardia (NASDAQ:BCDA)

SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today

United statesUniversity of wisconsinCarl pepineDavid mcclungMiranda petoPeter altmanCardiamp cell therapy programNational principal investigatorsUniversity of florida at gainesvilleBiocardia incNational principal investigatorStatistical data analysis centerExchange commission onMaryland stem cell research fundCell therapyHeart failure